Vascular and metabolic response to bevacizumab-containing regimens in two patients with colorectal liver metastases measured by dynamic contrast-enhanced MRI and Dynamic 18F-FDG-PET

Clinical Colorectal Cancer

Volumn 10, Issue 1, 2011, Pages

  Vriens, Dennis ^a   De Geus Oei, Lioe Fee ^a   Heerschap, Arend ^a   Van Laarhoven, Hanneke W M ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenic inhibitors; Chemotherapy; Colorectal carcinoma; DCE MRI; Therapy monitoring

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANGIOGENESIS INHIBITOR; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CARCINOMATOUS PERITONITIS; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE COURSE; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG UPTAKE; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; INOPERABLE CANCER; LAPAROSCOPIC SURGERY; LIVER METASTASIS; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROSTATECTOMY; SKIN TOXICITY; CASE REPORT; COLORECTAL TUMOR; DRUG MONITORING; INSTRUMENTATION; LIVER TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DRUG MONITORING; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 80053417416     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.3816/CCC.2011.n.010     Document Type: Article

References (25)

1. CJ Punt New options and old dilemmas in the treatment of patients with advanced colorectal cancer Ann Oncol 15 2004 1453 1459 (Pubitemid 39409733)
2. RK Jain Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 2001 987 989 (Pubitemid 32937367)
3. H Hurwitz, L Fehrenbacher, W Novotny et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
4. FF Kabbinavar, J Hambleton, RD Mass et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 2005 3706 3712
5. FF Kabbinavar, HI Hurwitz, J Yi et al. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials J Clin Oncol 27 2009 199 205
6. FF Kabbinavar, J Schulz, M McCleod et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol 23 2005 3697 3705
7. PS Tofts, G Brix, DL Buckley et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols J Magn Reson Imaging 10 1999 223 232 (Pubitemid 29463104)
8. HB Larsson, M Stubgaard, JL Frederiksen et al. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors Magn Reson Med 16 1990 117 131 (Pubitemid 20353802)
9. PS Tofts, AG Kermode Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts Magn Reson Med 17 1991 357 367
10. ML George, AS Dzik-Jurasz, AR Padhani et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer Br J Surg 88 2001 1628 1636 (Pubitemid 33124241)
11. MD Pickles, M Lowry, DJ Manton et al. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy Breast Cancer Res Treat 91 2005 1 10 (Pubitemid 40684933)
12. JP Delille, PJ Slanetz, ED Yeh et al. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study Radiology 228 2003 63 69 (Pubitemid 36736070)
13. A Thukral, DM Thomasson, CK Chow et al. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab-initial experience Radiology 244 2007 727 735 (Pubitemid 47292083)
14. CS Patlak, RG Blasberg, JD Fenstermacher Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data J Cereb Blood Flow Metab 3 1983 1 7 (Pubitemid 13129630)
15. L Sokoloff, M Reivich, C Kennedy et al. The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat J Neurochem 28 1977 897 916 (Pubitemid 8098854)
16. LF de Geus-Oei, HF Van der Heijden, EP Visser et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer J Nucl Med 48 2007 1592 1598 (Pubitemid 47572705)
17. LF de Geus-Oei, HW Van Laarhoven, EP Visser et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer Ann Oncol 19 2008 348 352 (Pubitemid 351201718)
18. HW Van Laarhoven, LF de Geus-Oei, B Wiering et al. Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET Radiology 237 2005 181 188 (Pubitemid 41346162)
19. HW Van Laarhoven, DW Klomp, M Rijpkema et al. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil NMR Biomed 20 2007 128 140 (Pubitemid 46470935)
20. D Vriens, HW Van Laarhoven, JJ Van Asten et al. Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate J Nucl Med 50 2009 1777 1784
21. T Ruers, F Van Coevorden, J Pierie et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Interim results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC) J Clin Oncol 26 15 suppl 2008 181s (abstract 4012).
22. P Therasse, SG Arbuck, EA Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
23. J Tol, M Koopman, A Cats et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
24. SB Wedam, JA Low, SX Yang et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer J Clin Oncol 24 2006 769 777 (Pubitemid 46622044)
25. J Baar, P Silverman, J Lyons et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers Clin Cancer Res 15 2009 3583 3590